Core Viewpoint - The successful administration of the first patient in the Phase I clinical trial of IMC-003/IMM72 marks a significant milestone for the company and lays a solid foundation for subsequent clinical trials [1] Group 1: Clinical Trial Progress - The first patient has been successfully dosed in the Phase I clinical trial of IMC-003/IMM72 [1] - This event signifies a major milestone in the clinical research of IMC-003/IMM72 [1] Group 2: Product Information - IMC-003/IMM72 is a next-generation ActRIIA-Fc fusion protein developed through genetic modification, featuring higher activity and quality [1] - The company holds global intellectual property rights as well as development and commercialization rights for IMC-003/IMM72 [1]
宜明昂科-B(01541)：IMC-003/IMM72第一期临床试验的首名患者已成功给药